Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer closes R&D unit that spawned $7.1B anti-TL1A med
The now-shuttered R&D subunit helped spawn new medicines, including Roivant's $7.1 billion anti-TL1A med.
Max Bayer
Apr 17, 2024 7:00am
Canaan adds $100M-plus, Pfizer vet to guide fresh biotech bets
Apr 17, 2024 7:00am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
AACR: Dogs, smoothies and AstraZeneca's nap-worthy carpet
Apr 8, 2024 5:00am
Headlands opens fifth trial site for Pfizer diversity pact
Apr 2, 2024 12:00pm
Roivant's inflammatory med is back on track with ph. 2 NIU data
Apr 2, 2024 10:37am